Novel Comprehensive Proteome Analyses of Metastasis

转移的新型综合蛋白质组分析

• 批准号: 6401270
• 负责人: DAVID W. SPEICHER
• 金额: $ 16.59万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2002-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6401270
• 关键词: MCF7 cell; SCID mouse; breast neoplasms; cell migration; gel electrophoresis; liquid chromatography mass spectrometry; metastasis; neoplasm /cancer invasiveness; oncoproteins; proteomics

The overall goal of this proposal is to apply several novel techniques to comprehensive quantitative comparisons of human breast cancer protein profiles focusing on changes associated with invasive/ metastatic potential. Our global proteome strategy should result in reliable quantitative comparisons of up to 10,000 proteins instead of the 1,500 to 2,500 protein spots typically detected on high resolution 2D gels. The most novel and key part of this strategy is a new method that we recently developed for prefractionating whole cell extracts prior to 2D PAGE. This method, termed microscale solution IEF (mu sol-IEF), uses small chambers separated by large pore acrylamide discs with immobilines at specific pH's to separate cell extracts into well resolved pools based upon pI's. A second novel feature of our global proteome strategy is use of slightly overlapping (about +/-0.1 pH) custom-made narrow pH range IPG gels tailored to match mu sol-IEF pools, rather than existing commercial 1 pH unit IPG gels with either 0 or 0.5 pH unit overlaps. A third novel feature is use of high-resolution 1D gels coupled with LC- MS-MS to analyze the insoluble proteins and large soluble proteins (100-500+ kDa). These two protein groups represent >25% of total cell protein mass, but are usually ignored in 2D protein profile comparisons. Finally, we recently optimized femtomole in-gel trypsin digestion to improve sensitivity and reliability of MALDI MS and LC-MS/MS identifications of targeted proteins. Our preliminary results show each of these techniques is very promising, but the feasibility of reliably quantitating 7,500 to 10,000+ proteins in human tumor cells remains to be demonstrated. The one year R21 phase will further optimize and integrate these methods to demonstrate proof-of-principle of our integrated global proteome analysis strategy using human breast cancer cells. The three year R33 phase will then apply the optimized global strategy to comparisons of multiple human breast cancer cell lines and tumors to identify protein changes associated with increased invasion and metastatic potential.

这项建议的总体目标是应用几种新技术对人类乳腺癌蛋白质图谱进行全面的定量比较，重点是与侵袭/转移潜力相关的变化。我们的全球蛋白质组策略应该能够对多达10,000个蛋白质进行可靠的定量比较，而不是通常在高分辨率2D凝胶上检测到的1,500到2,500个蛋白质点。这一策略最新颖和最关键的部分是我们最近开发的一种新方法，用于在2D PAGE之前预分提整个细胞提取液。这种方法被称为微尺度溶液IEF(MU Sol-IEF)，使用由大孔丙烯酰胺盘分隔的小室，在特定pH下使用固定素将细胞提取液分离到基于等电点的良好分辨池中。我们全球蛋白质组策略的第二个新特征是使用略微重叠(大约+/-0.1 pH)定制的窄pH范围IPG凝胶，以匹配Mu Sol-IEF池，而不是现有的商业1 pH单位IPG凝胶，具有0或0.5 pH单元重叠。第三个新特征是使用高分辨率一维凝胶与LC-MS-MS联用来分析不溶性蛋白质和大的可溶性蛋白质(100-500+kDa)。这两个蛋白质组占细胞总蛋白质质量的25%，但在2D蛋白质图谱比较中通常被忽略。最后，我们最近优化了飞摩尔凝胶内胰酶消化，以提高MALDI MS和LC-MS/MS鉴定目标蛋白质的灵敏度和可靠性。我们的初步结果表明，这些技术中的每一种都非常有希望，但可靠地定量人类肿瘤细胞中7,500至10,000+蛋白质的可行性仍有待验证。为期一年的R21阶段将进一步优化和整合这些方法，以证明我们使用人类乳腺癌细胞的综合全球蛋白质组分析策略的原理。然后，三年的R33阶段将应用优化的全球策略对多个人类乳腺癌细胞系和肿瘤进行比较，以确定与增加侵袭性和转移潜力相关的蛋白质变化。